|
EP1899364B2
(en)
|
2005-05-17 |
2024-10-30 |
University of Connecticut |
Compositions and methods for immunomodulation in an organism
|
|
SG176468A1
(en)
|
2005-12-02 |
2011-12-29 |
Sinai School Medicine |
Chimeric viruses presenting non-native surface proteins and uses thereof
|
|
WO2007084342A2
(en)
|
2006-01-13 |
2007-07-26 |
The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health |
Codon optimi zed il- 15 and il- 15r-alpha genes for expression in mammalian cells
|
|
CA3028038C
(en)
|
2007-05-11 |
2021-08-10 |
Altor Bioscience Corporation |
Fusion molecules and il-15 variants
|
|
DK2173378T3
(da)
|
2007-06-27 |
2014-05-12 |
Admune Therapeutics Llc |
Komplekser af il-15 og il-15ralfa og anvendelser deraf
|
|
EP4385570A3
(en)
|
2010-09-21 |
2024-09-11 |
Altor BioScience, LLC |
Multimeric il-15 soluble fusion molecules and methods of making and using same
|
|
WO2018112219A1
(en)
*
|
2016-12-14 |
2018-06-21 |
Nant Holdings Ip, Llc |
Superkine
|
|
US11053299B2
(en)
|
2010-09-21 |
2021-07-06 |
Immunity Bio, Inc. |
Superkine
|
|
DK2663579T3
(en)
|
2011-01-14 |
2017-07-31 |
Univ California |
THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
|
|
CA2869786A1
(en)
*
|
2012-06-08 |
2013-12-12 |
Alkermes, Inc. |
Fusion polypeptides comprising mucin-domain polypeptide linkers
|
|
AU2013334610B2
(en)
|
2012-10-24 |
2018-09-13 |
Novartis Ag |
IL-15R alpha forms, cells expressing IL-15R alpha forms, and therapeutic uses of IL-15R alpha and IL-15/IL-15R alpha complexes
|
|
BR112015013557B1
(pt)
*
|
2012-12-11 |
2021-12-14 |
Albert Einstein College Of Medicine |
Sistema, método, método para determinar o efeito de um resíduo de aminoácido predeterminado de uma primeira proteína sobre a ligação da primeira proteína a uma segunda proteína e polipeptídeo pd-l1 mutante
|
|
JP6596411B2
(ja)
|
2013-03-14 |
2019-10-23 |
アイカーン スクール オブ メディシン アット マウント サイナイ |
ニューカッスル病ウイルス及びその使用
|
|
CN109395064A
(zh)
|
2013-04-19 |
2019-03-01 |
赛腾制药 |
降低的血管渗漏综合征的细胞因子衍生治疗
|
|
EP3783098A1
(en)
*
|
2013-05-14 |
2021-02-24 |
Board Of Regents, The University Of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
EP3659622A1
(en)
*
|
2013-08-08 |
2020-06-03 |
Cytune Pharma |
Combined pharmaceutical composition
|
|
PL3444271T3
(pl)
|
2013-08-08 |
2022-03-07 |
Cytune Pharma |
Modulokiny oparte na il-15 i domenie sushi il-15ralfa
|
|
EP4043036A1
(en)
|
2013-09-27 |
2022-08-17 |
Massachusetts Institute of Technology |
Carrier-free biologically-active protein nanostructures
|
|
MX374391B
(es)
*
|
2014-01-08 |
2025-03-06 |
Shanghai hengrui pharmaceutical co ltd |
Proteina heterodimérica il-15 y usos de la misma.
|
|
CN113637692A
(zh)
*
|
2014-01-15 |
2021-11-12 |
卡德门企业有限公司 |
免疫调节剂
|
|
KR102375998B1
(ko)
|
2014-02-14 |
2022-03-21 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
키메라 항원 수용체 및 제조방법
|
|
KR102407019B1
(ko)
|
2014-02-27 |
2022-06-08 |
머크 샤프 앤드 돔 코포레이션 |
암의 치료를 위한 결합 방법
|
|
EP2915569A1
(en)
*
|
2014-03-03 |
2015-09-09 |
Cytune Pharma |
IL-15/IL-15Ralpha based conjugates purification method
|
|
WO2015164107A1
(en)
|
2014-04-23 |
2015-10-29 |
Emory University |
Compositions of gm-csf and interleukin fusions for immune modulation and uses related thereto
|
|
EP3805371A1
(en)
|
2014-05-15 |
2021-04-14 |
National University of Singapore |
Modified natural killer cells and uses thereof
|
|
PL3160498T3
(pl)
*
|
2014-06-30 |
2022-02-21 |
Altor Bioscience Corporation |
Cząsteczki na bazie IL-15 i sposoby ich zastosowania
|
|
WO2016018920A1
(en)
|
2014-07-29 |
2016-02-04 |
Admune Therapeutics Llc |
Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
CA2964367C
(en)
|
2014-10-14 |
2024-01-30 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
EP3221351B1
(en)
*
|
2014-11-19 |
2024-11-13 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for cancer treating conditions relating to over expressions of epha2
|
|
EP3235830B1
(en)
*
|
2014-12-19 |
2020-09-02 |
Jiangsu Hengrui Medicine Co., Ltd. |
Interleukin 15 protein complex and use thereof
|
|
CN104830884A
(zh)
*
|
2015-01-22 |
2015-08-12 |
苏州大学 |
一种携带IL-15/sIL-15Ra融合基因的微环DNA表达载体的构建方法
|
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
CN112574316A
(zh)
*
|
2015-07-02 |
2021-03-30 |
博际生物医药科技(杭州)有限公司 |
用于肿瘤靶向治疗的白细胞介素-15融合蛋白
|
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
|
WO2017019896A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
US11034752B2
(en)
|
2015-08-12 |
2021-06-15 |
Massachusetts Institute Of Technology |
Cell surface coupling of nanoparticles
|
|
KR20180125435A
(ko)
*
|
2015-09-25 |
2018-11-23 |
알토 바이오사이언스 코포레이션 |
이식편 대 종양 활성을 현저하게 향상시키는 인터루킨-15 수퍼아고니스트
|
|
SG10201912792YA
(en)
|
2015-10-06 |
2020-02-27 |
Univ Minnesota |
Therapeutic compounds and methods
|
|
WO2017106656A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
|
WO2017143092A1
(en)
|
2016-02-19 |
2017-08-24 |
Nant Holdings Ip, Llc |
Methods of immunogenic modulation
|
|
KR20190019068A
(ko)
|
2016-05-18 |
2019-02-26 |
큐 바이오파마, 인크. |
T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
|
|
CN109689096A
(zh)
|
2016-05-18 |
2019-04-26 |
阿尔伯特爱因斯坦医学院公司 |
变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
|
|
CA3024509A1
(en)
*
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
CN109496217B
(zh)
*
|
2016-05-27 |
2023-10-20 |
阿尔托生物科学有限公司 |
具有cd3结合域的基于多聚体il-15的分子的构造和表征
|
|
JP7185530B2
(ja)
*
|
2016-06-13 |
2022-12-07 |
トルク セラピューティクス， インコーポレイテッド |
免疫細胞機能を促進するための方法および組成物
|
|
US20190297861A1
(en)
*
|
2016-07-12 |
2019-10-03 |
Kymab Limited |
Animals, cells, ligands, polypeptides & methods
|
|
US12186342B2
(en)
|
2016-09-23 |
2025-01-07 |
The Regents Of The University Of California |
Autologous irradiated whole cell tumor vaccines lentivirally engineered to express CD80, IL-15 and IL-15 receptor alpha
|
|
MA46534A
(fr)
*
|
2016-10-14 |
2019-08-21 |
Xencor Inc |
Protéines de fusion fc hétérodimères il15/il15r
|
|
CN109952370B
(zh)
*
|
2016-10-19 |
2023-09-08 |
豪夫迈·罗氏有限公司 |
用于产生免疫缀合物的方法
|
|
SG11201903306SA
(en)
*
|
2016-10-21 |
2019-05-30 |
Altor Bioscience Corp |
Multimeric il-15-based molecules
|
|
PT3558339T
(pt)
|
2016-12-22 |
2024-03-15 |
Cue Biopharma Inc |
Polipeptídeos multiméricos moduladores de células t e métodos de utilização dos mesmos
|
|
CN108250301A
(zh)
*
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多靶点嵌合抗原受体
|
|
CN108250302A
(zh)
*
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多功能蛋白质
|
|
US11851471B2
(en)
|
2017-01-09 |
2023-12-26 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
WO2018134784A1
(en)
|
2017-01-20 |
2018-07-26 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
EP3570869A1
(en)
|
2017-01-20 |
2019-11-27 |
Novartis AG |
Combination therapy for the treatment of cancer
|
|
JP7191030B2
(ja)
*
|
2017-03-06 |
2022-12-16 |
アルター・バイオサイエンス・コーポレーション |
Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合
|
|
CA3054955A1
(en)
|
2017-03-15 |
2018-09-20 |
Cue Biopharma, Inc. |
Methods for modulating an immune response
|
|
CA3056439A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
SG11201908337VA
(en)
|
2017-03-27 |
2019-10-30 |
Nat Univ Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
|
US20190048055A1
(en)
|
2017-03-31 |
2019-02-14 |
Altor Bioscience Corporation |
Alt-803 in combination with anti-cd38 antibody for cancer therapies
|
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
|
WO2018229706A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
WO2018236890A1
(en)
|
2017-06-20 |
2018-12-27 |
Nantkwest, Inc. |
Nk-92 cells and il-15 agonist combination therapy
|
|
CN118853581A
(zh)
|
2017-06-21 |
2024-10-29 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(CARs)、组合物及其使用方法
|
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
|
CA3068841A1
(en)
|
2017-07-03 |
2019-01-10 |
Torque Therapeutics, Inc. |
Fusion molecules targeting immune regulatory cells and uses thereof
|
|
UA125971C2
(uk)
|
2017-07-25 |
2022-07-20 |
Джянгсу Хенгруй Медісін Ко., Лтд. |
Фармацевтична композиція, яка містить протеїновий комплекс il-15, та її застосування
|
|
US11161890B2
(en)
|
2017-08-28 |
2021-11-02 |
Altor Bioscience LLC. |
IL-15-based fusions to IL-7 and IL-21
|
|
CA3074826A1
(en)
|
2017-09-05 |
2019-03-14 |
Torque Therapeutics, Inc. |
Therapeutic protein compositions and methods of making and using the same
|
|
JP7710644B2
(ja)
|
2017-10-12 |
2025-07-22 |
アイセル・ジーン・セラピューティクス・インコーポレイテッド |
複数の抗原を標的とするｃｏｍｐｏｕｎｄキメラ抗原受容体（ｃＣＡＲ）の組成物およびその使用方法
|
|
CN109705211B
(zh)
|
2017-10-26 |
2020-08-18 |
苏州复融生物技术有限公司 |
一种IgG1 Fc单体及其应用
|
|
EP3717008A1
(en)
|
2017-12-01 |
2020-10-07 |
Merus N.V. |
Use of bispecific antibody and il-15 for combination therapy
|
|
CA3086040A1
(en)
|
2017-12-19 |
2019-06-27 |
Blaze Bioscience, Inc. |
Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
|
|
US11413050B2
(en)
|
2018-01-05 |
2022-08-16 |
Theragi, LLC |
Surgical clip and deployment system
|
|
EP3737689A4
(en)
|
2018-01-09 |
2021-12-01 |
Cue Biopharma, Inc. |
MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
|
|
CN111936156A
(zh)
|
2018-02-02 |
2020-11-13 |
诺华股份有限公司 |
用于治疗癌症的STING激动剂和IL-15/IL15-Ra的组合
|
|
SG11202007156QA
(en)
|
2018-02-09 |
2020-08-28 |
Nat Univ Singapore |
Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
KR102812714B1
(ko)
*
|
2018-02-26 |
2025-05-27 |
신톡스, 인크. |
Il-15 접합체 및 이의 용도
|
|
BR112020016859A2
(pt)
|
2018-02-28 |
2020-12-29 |
Pfizer Inc. |
Variantes de il-15 e usos da mesma
|
|
EP3773657A4
(en)
*
|
2018-03-26 |
2021-12-08 |
Altor Bioscience LLC |
ANTI-PDL1, IL-15 AND TGF BETA RECEPTOR COMBINATION MOLECULES
|
|
SG11202008976YA
(en)
|
2018-04-02 |
2020-10-29 |
Nat Univ Singapore |
Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
|
|
WO2019195420A1
(en)
|
2018-04-04 |
2019-10-10 |
Nant Holding IP, LLC |
Advanced avartar dendritic cells
|
|
MX2020010910A
(es)
|
2018-04-18 |
2021-02-09 |
Xencor Inc |
Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
|
|
US20190352362A1
(en)
*
|
2018-04-18 |
2019-11-21 |
Xencor, Inc. |
LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
|
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
SG11202010159RA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
|
CN111988991B
(zh)
*
|
2018-04-26 |
2023-09-15 |
豪夫迈·罗氏有限公司 |
用于追踪动物种群中的动物的方法和系统
|
|
CN110437339B
(zh)
|
2018-05-04 |
2021-08-13 |
免疫靶向有限公司 |
一种以白介素15为活性成分的融合蛋白型药物前体
|
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
CN112654633B
(zh)
|
2018-06-22 |
2025-05-09 |
科优基因公司 |
基于细胞因子的可生物活化药物及其使用方法
|
|
WO2019246379A1
(en)
*
|
2018-06-22 |
2019-12-26 |
Cugene Inc. |
Novel interleukin-15 (1l-15) fusion proteins and uses thereof
|
|
WO2019246563A1
(en)
*
|
2018-06-22 |
2019-12-26 |
Kite Pharma, Inc. |
Chimeric transmembrane proteins and uses thereof
|
|
WO2020023713A1
(en)
*
|
2018-07-26 |
2020-01-30 |
Nantbio, Inc. |
Tri-cytokine txm compositions and methods
|
|
JP2021532796A
(ja)
*
|
2018-07-30 |
2021-12-02 |
晋宇 張 |
タンパク質ヘテロ二量体およびその使用
|
|
US12350316B2
(en)
|
2018-08-16 |
2025-07-08 |
Nantbio, Inc. |
IL7-IL 15 TxM compositions and methods
|
|
WO2020037215A1
(en)
|
2018-08-17 |
2020-02-20 |
Icahn School Of Medicine At Mount Sinai |
Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
|
|
KR102839381B1
(ko)
|
2018-08-29 |
2025-07-28 |
내셔널 유니버시티 오브 싱가포르 |
유전적으로 변형된 면역 세포의 생존 및 확장을 특이적으로 자극하는 방법
|
|
CN113365663B
(zh)
|
2018-08-30 |
2025-11-21 |
免疫生物公司 |
单链嵌合多肽和其用途
|
|
JP7474769B2
(ja)
*
|
2018-08-30 |
2024-04-25 |
エイチシーダブリュー バイオロジックス インコーポレイテッド |
一本鎖および多鎖キメラポリペプチドならびにその使用方法
|
|
KR20250160211A
(ko)
|
2018-08-30 |
2025-11-11 |
이뮤니티바이오, 인크. |
다중-사슬 키메라 폴리펩타이드 및 이의 용도
|
|
US20220002370A1
(en)
|
2018-09-27 |
2022-01-06 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
|
WO2020077180A1
(en)
|
2018-10-11 |
2020-04-16 |
Nantcell, Inc. |
Treatment of immunosuppressed subjects
|
|
MA53862A
(fr)
|
2018-10-12 |
2022-01-19 |
Xencor Inc |
Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci
|
|
WO2020081841A1
(en)
|
2018-10-19 |
2020-04-23 |
Regents Of The University Of Minnesota |
Nk engager molecules and methods of use thereof
|
|
KR20210102917A
(ko)
|
2018-12-13 |
2021-08-20 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
종양 질환을 치료하기 위한 il-15 단백질 복합체 연합 pd-l1 항체의 용도
|
|
WO2020130829A1
(en)
|
2018-12-20 |
2020-06-25 |
Merus N.V. |
Clec12axcd3 bispecific antibodies and methods for the treatment of disease
|
|
EP3897853A1
(en)
|
2018-12-20 |
2021-10-27 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
|
|
EP3908314A4
(en)
*
|
2019-01-11 |
2023-05-10 |
Memorial Sloan Kettering Cancer Center |
MULTIMERIZATION OF IL-15/IL-15R ALPHA-FC COMPLEXES TO IMPROVE IMMUNOTHERAPY
|
|
WO2020150364A1
(en)
*
|
2019-01-15 |
2020-07-23 |
Altor Bioscience, Llc |
Human immunodeficiency virus-specific t cell receptors
|
|
AU2020232691B2
(en)
|
2019-03-05 |
2023-06-29 |
Nkarta, Inc. |
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
US20220218789A1
(en)
|
2019-05-10 |
2022-07-14 |
Nant Holdings Ip, Llc |
Nogapendekin Alfa-Inbakicept For Immune Stimulant Therapies And Treatment Of Viral Infections
|
|
US12085571B2
(en)
|
2019-06-13 |
2024-09-10 |
Immunitybio, Inc. |
Biological deposit labeling and tracking including isotope, rare earth metal or mitochondria tags
|
|
US11738052B2
(en)
|
2019-06-21 |
2023-08-29 |
HCW Biologics, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
|
US11453862B2
(en)
|
2019-07-08 |
2022-09-27 |
Immunitybio, Inc. |
Mononuclear cell derived NK cells
|
|
SG11202104339WA
(en)
|
2019-07-08 |
2021-05-28 |
Nantkwest Inc |
Mononuclear cell derived nk cells
|
|
US11364291B1
(en)
|
2019-07-18 |
2022-06-21 |
Nantcell, Inc. |
Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
|
|
CN110478474B
(zh)
*
|
2019-08-21 |
2020-06-02 |
启辰生生物科技(珠海)有限公司 |
免疫调节剂、疫苗、细胞及应用
|
|
CN114787196A
(zh)
*
|
2019-08-29 |
2022-07-22 |
南特生物科学公司 |
修饰的n-810及其方法
|
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
RU2753282C2
(ru)
*
|
2019-09-19 |
2021-08-12 |
Закрытое Акционерное Общество "Биокад" |
ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
US20220402988A1
(en)
*
|
2019-12-05 |
2022-12-22 |
Immune Targeting Inc. |
Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof
|
|
CN113135996A
(zh)
*
|
2019-12-09 |
2021-07-20 |
启愈生物技术(上海)有限公司 |
一种双特异抗体及其应用
|
|
WO2021138346A1
(en)
*
|
2019-12-31 |
2021-07-08 |
Navrogen, Inc. |
Composition and use of engineered monoclonal antibodies refractory to tumor immuno-suppressive factors
|
|
CA3163838A1
(en)
|
2020-01-08 |
2021-07-15 |
Vipin Suri |
Compositions and methods for tunable regulation of transcription
|
|
WO2021142476A1
(en)
*
|
2020-01-12 |
2021-07-15 |
Dragonfly Therapeutics, Inc. |
Single-chain polypeptides
|
|
US20230110606A1
(en)
*
|
2020-01-31 |
2023-04-13 |
Auragent Bioscience, Llc |
Ultrabright fluorescent nanocomposite structures for enhanced fluorescent bioassays
|
|
EP4100425A1
(en)
*
|
2020-02-05 |
2022-12-14 |
Novartis AG |
Cho cell expressing il-15 heterodimers
|
|
WO2021163298A1
(en)
|
2020-02-11 |
2021-08-19 |
HCW Biologics, Inc. |
Methods of activating regulatory t cells
|
|
KR20220140535A
(ko)
|
2020-02-11 |
2022-10-18 |
에이치씨더블유 바이올로직스, 인크. |
크로마토그래피 수지 및 이의 용도
|
|
CA3169231A1
(en)
|
2020-02-11 |
2021-08-19 |
HCW Biologics, Inc. |
Methods of treating age-related and inflammatory diseases
|
|
CN120518773A
(zh)
|
2020-03-11 |
2025-08-22 |
南特细胞公司 |
蛋白质治疗剂
|
|
WO2021202354A1
(en)
*
|
2020-03-30 |
2021-10-07 |
Proviva Therapeutics (Hong Kong) Limited |
Il-2/il-15 compositions and methods of use thereof
|
|
BR112022020973A2
(pt)
|
2020-04-22 |
2022-12-06 |
Novartis Ag |
Composições farmacêuticas e produtos farmacêuticos de interleucina-15 humana heterodimérica (hetil-15)
|
|
JP7734693B2
(ja)
|
2020-04-29 |
2025-09-05 |
イミュニティーバイオ インコーポレイテッド |
抗ｃｄ２６タンパク質及びそれらの使用法
|
|
WO2021231376A2
(en)
|
2020-05-12 |
2021-11-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
US11318189B1
(en)
|
2020-05-13 |
2022-05-03 |
Nantcell, Inc. |
IL-15 agonist drug combinations for immune therapy
|
|
US12024545B2
(en)
|
2020-06-01 |
2024-07-02 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
|
US20230226203A1
(en)
*
|
2020-06-18 |
2023-07-20 |
Proviva Therapeutics (Hong Kong) Limited |
Activatable procytokines
|
|
US12252525B2
(en)
|
2020-07-31 |
2025-03-18 |
Nantbio, Inc. |
Chimeric T cell receptors, nucleic acids, and methods of making and using the same
|
|
CA3190098A1
(en)
|
2020-08-03 |
2022-02-10 |
Nantcell, Inc. |
Drug-specific pharmacokinetic assay for il-15 superagonist
|
|
JP2023541366A
(ja)
|
2020-09-09 |
2023-10-02 |
キュー バイオファーマ， インコーポレイテッド |
１型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
BR112023004860A2
(pt)
*
|
2020-09-16 |
2024-02-06 |
Beigene Ltd |
Construto de interleucina 15 (il15), composição farmacêutica, método de tratamento de câncer e método para aumentar a sobrevivência de uma célula imune
|
|
TW202235431A
(zh)
|
2020-11-25 |
2022-09-16 |
美商艾希利歐發展股份有限公司 |
腫瘤特異性可裂解連接子
|
|
US11591381B2
(en)
|
2020-11-30 |
2023-02-28 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
TW202237827A
(zh)
|
2020-12-03 |
2022-10-01 |
美商世紀治療股份有限公司 |
經基因工程改造之細胞及其用途
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
WO2022133169A1
(en)
|
2020-12-18 |
2022-06-23 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
|
CA3203180A1
(en)
*
|
2020-12-23 |
2022-06-30 |
Robert Tighe |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US11473060B2
(en)
|
2020-12-30 |
2022-10-18 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into NK cells
|
|
CN113321736B
(zh)
*
|
2020-12-30 |
2024-01-09 |
苏州复融生物技术有限公司 |
一种长效化白介素15融合蛋白及其制备方法和应用
|
|
CA3206549A1
(en)
|
2021-01-29 |
2022-08-04 |
Frederick G. Vogt |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
CN117440972A
(zh)
|
2021-03-24 |
2024-01-23 |
奥克梅斯公司 |
Upar抗体和具有所述抗体的融合蛋白
|
|
EP4314033A4
(en)
*
|
2021-03-31 |
2025-04-23 |
Anwita Biosciences, Inc. |
FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
|
|
US20250197525A1
(en)
|
2021-04-28 |
2025-06-19 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
|
CN113321740B
(zh)
*
|
2021-05-08 |
2023-07-18 |
上海交通大学 |
一种融合蛋白及其制备方法和用途
|
|
KR20240024858A
(ko)
*
|
2021-05-28 |
2024-02-26 |
악소 바이오파마슈티컬 인코포레이티드 |
sPD-1과 IL-15를 갖는 이중특이적 Fc 융합 단백질
|
|
EP4351320A1
(en)
|
2021-06-09 |
2024-04-17 |
ImmunityBio, Inc. |
Methods and systems for producing a protein of interest in a plant
|
|
CN113736810B
(zh)
*
|
2021-09-08 |
2024-05-24 |
苏州因特药物研发有限公司 |
构建体、载体、蛋白、细胞、制备方法、产品及应用
|
|
US20240415964A1
(en)
|
2021-11-02 |
2024-12-19 |
Immunitybio, Inc. |
Natural killer cells for chordoma therapy
|
|
WO2023086772A1
(en)
|
2021-11-12 |
2023-05-19 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and nkg2d
|
|
JP2025504475A
(ja)
|
2022-01-22 |
2025-02-12 |
ナントセル，インコーポレーテッド |
Ｃｔｌａ４及びｉｌ－１５の融合分子
|
|
CN116854821A
(zh)
|
2022-08-15 |
2023-10-10 |
海徕科(北京)生物技术有限公司 |
IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途
|
|
EP4335870A1
(en)
|
2022-09-06 |
2024-03-13 |
NantCell, Inc. |
Peptide therapeutics against sars-cov-2 spike protein
|
|
WO2024102636A1
(en)
|
2022-11-07 |
2024-05-16 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and mica/b
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
WO2024199355A1
(en)
*
|
2023-03-29 |
2024-10-03 |
Starna Therapeutics |
Nucleic acids encoding therapeutic polypeptides and lipid nanoparticle composition comprising the nucleic acids
|
|
WO2024253944A2
(en)
*
|
2023-06-06 |
2024-12-12 |
Jecho Laboratories, Inc. |
Interleukin-15 fusion protein and methods of use
|
|
WO2025010111A1
(en)
*
|
2023-07-05 |
2025-01-09 |
Nanotein Technologies, Inc. |
Cell signaling complexes and uses thereof
|
|
WO2025015318A2
(en)
|
2023-07-13 |
2025-01-16 |
Iovance Biotherapeutics, Inc. |
Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
|
|
US12473529B2
(en)
|
2023-07-18 |
2025-11-18 |
Nanotein Technologies, Inc. |
Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof
|
|
WO2025076124A1
(en)
*
|
2023-10-02 |
2025-04-10 |
Immunitybio, Inc. |
Methods of generating, stimulating, or increasing proliferation of different subsets of cd8+ t cells
|
|
WO2025085672A1
(en)
|
2023-10-17 |
2025-04-24 |
Xencor, Inc. |
Bispecific antibodies that bind to nkp46 and mica/b
|
|
US20250134974A1
(en)
*
|
2023-10-31 |
2025-05-01 |
Immunitybio, Inc. |
Multi-chain chimeric polypeptides and use thereof in the treatment of advanced solid tumors
|
|
CN118108809B
(zh)
*
|
2024-03-15 |
2025-02-28 |
西湖实验室(生命科学和生物医学浙江省实验室) |
一种跨膜荧光蛋白、水溶荧光蛋白及其用途
|